Abstract
The study aimed to evaluate the efficacy and safety of dose-escalated stereotactic body radiotherapy (SBRT) for primary lung cancer. Patients with peripherally located T1-2N0M0 primary lung cancer who underwent SBRT from April 2013 to December 2019 were included. Group A received 60Gy in five fractions with CyberKnife prescribed at 99% gross tumor volume. Group B received 48Gy in four fractions by a gantry-mounted linear accelerator, with isocenter prescription. Cumulative incidence of local failure (LF), progression free survival (PFS), overall survival (OS), and toxicity were retrospectively compared. Groups A and B comprised 39 and 36 patients, respectively. Group A had more patients without histological confirmation (p<.001) and showed lower V20 of bilateral lungs (p=.025). The median follow-up duration of Group A and B was 22.0 and 21.5 months, respectively, and the 2-year cumulative incidence of LF, PFS, and OS were .0%versus 11.6% (p=.065), 66.2%versus 62.7% (p=.694), 84.1%versus 81.1% (p=.827), respectively. There was no difference in Grade ≥ 2 toxicity rate between Groups A and B (7.7%vs. 11.1%; p=.704). Dose-escalated SBRT using CyberKnife showed reduced lung dose and potential benefits for improved local control with comparable toxicity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
